Neuromuscular

Kristine Yaffe, MD, distinguished professor at UCSF and SEQUINS Hall of Fame honoree, discusses dementia prevention, modifiable risk factors, and ongoing disparities in brain health and cognitive aging.

Thomas Crawford, MD, a pediatric neurologist at Johns Hopkins, discussed the FDA's recent approval of high-dose nusinersen for spinal muscular atrophy and SMA's evolving landscape of care.

A phase 2 trial found that the oral complement factor D inhibitor vemircopan did not demonstrate efficacy over placebo in adults with acetylcholine receptor antibody–positive generalized myasthenia gravis, leading to early termination of the study.

As a 2026 SEQUINS Hall of Fame honoree, James Galvin, MD, MPH, reflected on advancing equitable dementia care, culturally relevant cognitive assessment, and improving brain health outcomes across diverse communities.

Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.

As a 2026 SEQUINS Hall of Fame honoree, George Howard, DrPH, commented on decades of stroke disparities research, the impact of the REGARDS study, and why future efforts must focus more directly on upstream risk factors.

As a 2026 SEQUINS Hall of Fame honoree, Gretchen L. Birbeck, MD, MPH, reflected on her decades-long work advancing equity in global neurologic care and improving epilepsy outcomes in resource-limited settings.

As a 2026 SEQUINS Hall of Fame honoree, Edwin Trevathan, MD, MPH, reflects on global pediatric neurology, community-based care delivery, and the ongoing effort to reduce neurologic health inequities worldwide.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending May 9th, 2026. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 8, 2026.

Adam Vogel, PhD, Professor of Speech Neuroscience at The University of Melbourne and Chief Science Officer at Redenlab, discusses the emerging role of speech analytics as an objective, scalable biomarker in neurodegenerative disease research.

David Setboun, PharmD, MBA, CEO of PharmatrophiX, and Frank Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism targeting p75 signaling and its potential to modify neurodegenerative disease biology.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the FDA's decision, and also discussed the evolving SMA treatment landscape in general terms. [WATCH TIME: 11 minutes]

Bill Nye, science educator and advocate, reflects on Friedreich ataxia awareness, diagnostic challenges, and the evolving role of genetics and communication in advancing care.

Srikanth Muppidi, MD, a clinical professor of adult neurology at Stanford University, discussed phase 2 findings from the KYSA-6 trial of mivocabtagene autoleucel (miv-cel; KYV-101) in MG.

Amanda Piquet, MD, FAAN, spoke about data she presented at AAN's 2026 Meeting.

The director of the Neuromuscular Division at the Medical University of South Carolina shared post hoc CHAMPION-MG trial findings at MDA 2026, suggesting ravulizumab may enable corticosteroid reduction while maintaining or improving clinical outcomes. [WATCH TIME: 4 minutes]

Clene plans to pursue accelerated FDA approval for CNM-Au8 in ALS based primarily on neurofilament light biomarker data and phase 2 studies, with a confirmatory phase 3 trial expected to follow.

Following his symposium at the 2026 AAN Annual Meeting, science educator Bill Nye discussed his connection to Friedreich ataxia, emphasizing the importance of awareness, early diagnosis, and effective communication between clinicians and patients. [WATCH TIME: 4 minutes]

Aprill Lane, US Advocacy Lead for Rare Disease at UCB, discusses a new national initiative aimed at improving nutrition access and reducing daily disease burden for patients with myasthenia gravis.

New phase 2 data indicate that dazucorilant may reduce mortality risk in amyotrophic lateral sclerosis, with sustained effects observed through 2 years, although no significant improvement in functional outcomes was reported.

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology headlines you may have missed in April 2026, compiled into 1 place by the NeurologyLive® team.

The clinical professor of adult neurology at Stanford University discussed data he presented at AAN's 2026 Meeting [WATCH TIME: 4 minutes]